[1]Pennathur A,Gibson MK,Jobe BA,et al.Oesophageal carcinoma[J].Lancer,2013,381:400-412.
[2]Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].CA Cancer J Clin,2005,55:74-108.
[3]Luo Y, Mao Q, Wang X, et al. Radiotherapy for esophageal carcinoma: dose, response and survival[J]. Cancer Manag Res, 2017, 10:13-21.
[4]徐颖,陈美,金雪峰,等. 蟾毒灵体内外抗肿瘤作用及制剂研究进展[J]. 中国中药杂志,2014,39(15):2829-2833.
[5]田昕,罗颖,闫永波,等. 蟾蜍灵对人食管鳞癌EC9706细胞增殖及凋亡的影响[J]. 中国医学科学院学报, 2012,34(6):556-562.
[6]Yin PH, Liu X, Qiu YY, et al. Anti-tumor activity and apoptosis-regulation mechanisms of bufalin in various cancers: New hope for cancer patients[J]. Asian Pacific J Cancer Prev, 2012,13 (11), 5339-5343.
[7]Zhang X, Huang QB, Wang XH, et al. Bufalin enhances radiosensitivity of glioblastoma by suppressing mitochondrial function and DNA damage repair[J]. Biomed Pharmacother, 2017,94: 627-635.
[8]李二妮, 刘云鹏, 侯科佐, 等. 蟾蜍灵对人鼻咽癌细胞CNE-1 的放射增敏作用[J]. 中华肿瘤防治杂志, 2006,13(13):978-980.
[9]Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
[10]Kumagai K, Rouvelas L, Tsai JA, et al. Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers[J]. Br J Surg, 2014,101(4): 321-338.
[11]Wheeler JB, Reed CE. Epidemiology of esophageal cancer[J]. Surg Clin North Am, 2012, 92(5): 1077-1087.
[12]Ajani JA.Gastroesophageal cancers:progress and problems[J].J Natl Compr Canc Netw,2008,6(9):813-814.
[13]Fareed KR, Kaye P, Soomro LN, et al. Biomarkers of response to therapy in oesophago-gastric cancer[J]. Gut, 2009,58(1): 127-143.
[14]Gillies RS, Middleton MR, Blesing C. A reply to evidence-based radiation oncology: oesophagus[J]. Radiother Oncol, 2010,94(3): 387-388.
[15]Berger B,Belka C.Evidence-based radiation oncology:oesophagus[J].Radiother Oncol,2009,92(2):276-290.
[16]Gao Y, Li HX, Xu LT, et al. Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK[J]. Mol Biol Rep, 2012,39(2): 1683-1689.
[17]Jiang Y, Zhang Y, Luan J, et al. Effects of bufalin on the proliferation of human lung cancer cells and its molecular mechanisms of action[J]. Cytotechnology, 2010,62(6): 573-583.
[18]Zhu Z,Li E,Liu Y,et al.Inhibition of Jak-STAT3 pathway enhances bufalin-induced apoptosis in colon cancer SW620 cells[J].World J Surg Oncol,2012,10:228-235.
[19]Yeh JY, Huang WJ, Kan SF, et al. Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells[J]. Prostate, 2003, 54(2): 112-124.
[20]曾欢, 宋兴福, 董自强. 蟾蜍制剂诱导肿瘤细胞凋亡的研究进展[J]. 现代肿瘤医学, 2012, 20(4): 865-867.
[21]Yue M, Liu X, Ding Y, et al. Effect of bufalin on proliferation and apoptosis through ERK/RSK2 pathway in human esophageal carcinoma cell line xenografts in nude mice[J]. Zhonghua Zhong Liu Za Zhi, 2016. 38(5): 325-332.
[22]Lin S, Lv J, Peng P, et al. Bufadienolides induce p53-mediated apoptosis in esophageal squamous cell carcinoma cells in vitro and in vivo[J]. Oncol Lett, 2018, 15(2): 1566-1572.
[23]黄后宝, 夏东东,沈群山,等. 蟾毒灵对人膀胱癌T24细胞增殖和凋亡的影响.中国临床药理学与治疗学,2014,19(17):733-737.
[24]杨璐, 刘延国, 李际盛, 等. 蟾毒灵对非小细胞肺癌顺铂化疗的增敏作用及机制[J]. 山东大学学报, 2015,53(3): 6-11.
[25]徐颖, 陈美, 金雪峰, 等. 蟾毒灵体内外抗肿瘤作用及制剂研究进展[J]. 中国中药杂志,2014,39(15):2829-2833.
[26]Circu ML, Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis[J]. Free Radic Biol Med, 2010, 48(6):749-762.
[27]Li Y, Liu X, Gong P, et al. Bufalin inhibits human breast cancer tumorigenesis by inducing cell death through the ROS-mediated RIP1/RIP3/PARP-1 pathways[J]. Carcinogenesis, 2018, 39(5):700-707.
|